Biological systems are notoriously tough to model, especially when it comes to figuring out the axons, neurons, blood vessels, and other structural components of gray matter, or the tissue that makes ...

The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $10.84 / share. This is an increase of 48.75% from the prior estimate of $7.29 dated September 27, 2025. The ...

NEW YORK - September 9, 2025 (NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks ...

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Replimune ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the ...

LOS ANGELES, Aug. 5, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...

Replimune (NASDAQ:REPL) announced on Tuesday that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding its marketing application for its lead asset, RP1, declining ...

REPLIMUNE GROUP ($REPL) posted quarterly earnings results on Thursday, May 22nd. The company reported earnings of -$0.82 per share, missing estimates of -$0.77 by $0. ...

NEW DELHI: Rudrabhishek Enterprises (REPL) has received registration for small and medium real estate investment trusts (SM REITs) by the securities and exchange board of India (SEBI). SEBI first ...

Donald Trump made clear on the Philadelphia debate stage this week, as he has throughout his three presidential campaigns, the basis of his run for office. Trump is running on the platform that ...